Benefits
Antimicrobial activity in laboratory tests only
Berberine, one of goldenseal's alkaloids, inhibits a range of bacteria, fungi and protozoa in culture, and goldenseal extracts do the same in petri-dish tests. The published goldenseal work on immune function and respiratory infection is limited to laboratory studies and one study in rats; there is no controlled study in people. Nothing here has been shown to shorten a cold or clear an infection in a person, and berberine is poorly absorbed from the gut, under 5 percent, so blood levels after a goldenseal capsule are low.
Digestive use rests on isolated berberine, not on goldenseal
A 1987 randomized trial in Bangladesh gave 165 adults with acute infectious diarrhea a single 400 mg dose of isolated berberine sulfate. In the E. coli group, 42 percent had stopped having diarrhea at 24 hours versus 20 percent of controls; in the cholera group the effect was slight, and adding 1,200 mg of berberine to tetracycline gave no reduction in stool output over tetracycline alone. That was purified berberine at a dose a goldenseal capsule does not contain, given to patients with acute tropical infections. Goldenseal itself has never been tested for diarrhea.
Blood sugar: no goldenseal trial has measured it
Isolated berberine at 1,000 to 1,500 mg per day lowers fasting glucose and HbA1c in trials in type 2 diabetes. Goldenseal has never been tested against blood sugar, and it does not supply that amount of berberine. What goldenseal has been shown to do is reduce the absorption of metformin: in a study in 16 healthy adults it cut metformin exposure by about 23 percent, and in a crossover study in adults with type 2 diabetes exposure fell about 20 percent at metformin doses of 500 to 750 mg per day, though across all metformin doses the overall change was small enough to sit inside the no-effect range. Anyone taking a diabetes medicine should treat goldenseal as a possible interaction rather than a blood sugar aid.
Mucous membrane tonic: a traditional use, not a tested one
Nineteenth-century eclectic physicians used goldenseal as an astringent wash and tonic for inflamed mucous membranes, which is why it still appears in cold and sinus formulas. No study has measured mucus, congestion, sinus symptoms or gut inflammation in people taking goldenseal. Treat this as tradition, not as a demonstrated effect.
Mechanism of action
Berberine AMPK activation in cell and animal work
In cell and animal work, berberine activates AMP-activated protein kinase (AMPK) by inhibiting mitochondrial Complex I, which increases glucose uptake and fatty acid oxidation and damps NF-kB signalling. This is berberine pharmacology at concentrations reached with isolated berberine supplements. It has not been shown to occur after a goldenseal dose.
Antimicrobial membrane disruption
Berberine inserts into bacterial DNA, inhibiting topoisomerase II and DNA gyrase required for replication. Additionally, berberine disrupts bacterial membrane integrity, inhibits bacterial adhesion to epithelial cells, and reduces biofilm formation — providing several antimicrobial mechanisms in culture against gram-positive and gram-negative organisms. These are concentrations achieved in a test tube, not levels reached in blood after swallowing goldenseal.
Hydrastine mucosal astringency
Hydrastine is goldenseal's second major alkaloid and was historically used as a vasoconstrictor. The astringent, secretion-drying effect attributed to it comes from traditional practice rather than from measurement, and no study has compared goldenseal with isolated berberine for any mucosal condition.
Clinical trials
Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. J Infect Dis 1987;155(5):979-84 (PMID 3549923). Randomized controlled trial of berberine sulfate in 165 adults in Bangladesh with acute diarrhea from enterotoxigenic E. coli or Vibrio cholerae: a single 400 mg oral dose versus untreated control, and 1,200 mg plus tetracycline versus tetracycline alone in the cholera arms.
165 adults in Bangladesh with acute infectious diarrhea, given isolated berberine sulfate rather than goldenseal.
In the E. coli group, mean stool volumes were lower than controls over the three 8-hour periods after dosing, and 42 percent versus 20 percent of controls had stopped having diarrhea at 24 hours. In cholera the effect was slight, and 1,200 mg of berberine added to tetracycline produced no reduction in stool output over tetracycline alone. There was no placebo arm; the comparison was against untreated controls. The paper's own conclusion was that berberine is effective for E. coli diarrhea but that its activity against cholera is slight and not additive with tetracycline. This tested purified berberine sulfate at a dose roughly ten to forty times what a standard goldenseal capsule contains.
This is a summary of the published literature, not a study. Searching PubMed for goldenseal or Hydrastis with the clinical-trial filter returns six records, all of them drug-interaction pharmacokinetic studies. Searches for goldenseal with immune, common cold or upper respiratory outcomes return only laboratory work, one study in rats, and drug-interaction studies.
None. No people were studied, because no such trial exists.
Claims that goldenseal raises secretory IgA or natural killer cell activity come from traditional use, cell studies and one study of antibody production in rats, not from human trials. Goldenseal extracts do inhibit bacteria in culture. Berberine is poorly absorbed orally, under 5 percent, so blood levels after a goldenseal capsule are low. A 2020 critical review of goldenseal in Pharmacological Research concluded that large randomized double-blind clinical studies still need to be conducted on goldenseal supplements and their main alkaloids.